Article Text

  1. G Yamanaka1,
  2. C Ishii1,
  3. Y Suganami1,
  4. S Oana1,
  5. H Kawashima1,
  6. T Miyajima1,
  7. K Takekuma1,
  8. H Hoshika1
  1. 1Department of Pediatrics, Tokyo Medical University, Tokyo, Japan


Interleukin-1 gene family: interleukin-1β (IL-1β) and interleukin-1 receptor antagonist (IL-1RA) has been suggested to play a pathogenic role as an important mediator of epileptic seizure. In experimental models it has been reported that intracerebral application of IL-1β enhances epileptic activity while IL-1RA mediates anticonvulsant actions. In this study we analyzed serum and cerebrospinal fluid (CSF) levels of IL-1β and IL-1RA in 14 patients with age-dependent epileptic encephalopathy (ADEE), including: West syndrome (n = 11), early infantile epileptic encephalopathy with suppression-burst (n = 2), and malignant migrating partial seizures in infancy (n = 1). On comparison between pre- and post-improvement of symptom and EEG findings, serum IL-1RA levels post- (413.2±165.5 pg/ml) were significantly higher than those of pre- (251.5±125.4 pg/ml) improvement. Serum IL-1β levels (11–12 pg/ml) barely increased in three patients pre-improvement, and these levels decreased to be below detectable levels in all patients post-improvement. On comparison between recurrent and non-recurrent seizure groups regarding serum IL-1RA levels pre-improvement, the levels in the recurrent seizure group (212.8±139.0 pg/ml, n = 9) were lower than those in the non-recurrent seizure group (287.0±117.1 pg/ml, n = 5), but the difference was not significant. There was no difference in CSF IL-1RA levels between recurrent and non-recurrent seizure groups (137.3±69.7 vs. 134.6±63.6 pg/ml, respectively). CSF IL-1β levels were below detectable levels in all except for one patient (31.2 pg/ml). In conclusion, the serum IL-1RA level provided a basis for determining the effectiveness of treatment, and may become a valid predictive marker of ADEE severity.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.